<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Our recent work has shown the feasibility of using a refined immunomagnetic enrichment (IE) assay to detect cytokeratin 20-positive circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells (CK20 pCTCs) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients </plain></SENT>
<SENT sid="1" pm="."><plain>We attempted to improve the sensitivity for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> by detecting another intestinal-type differentiation marker, CDX2 pCTCs, using the same methodology </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: CDX2 pCTCs were detected in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> (CAD), benign colorectal diseases (BCD), other common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (OCC) and <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (NS) </plain></SENT>
<SENT sid="3" pm="."><plain>Statistical analysis was used to correlate CDX2 pCTCs to the clinicohistopathological factors, recurrence, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and survival after follow-up for 42 months in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: CDX2 pCTCs were detected in 81% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (73 out of 90, median number=21.5 CTCs), 7.5% CAD patients (3 out of 40), 0% patients with BCD (0 out of 90), 2.5% patients with OCC (2 out of 80) and 0% NS (0 out of 40) </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, statistical analysis showed that CDX2 pCTC numbers were associated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>- node-<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> stage and lymph node status </plain></SENT>
<SENT sid="6" pm="."><plain>Using the median CDX2 pCTC numbers as the cutoff points, stratified groups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients had significant differences in their recurrence and survival </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: This study showed that the refined IE assay can detect CDX2 pCTCs with high sensitivity and that CDX2 pCTCs can generate clinically important information for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>